Data / Form D filings / NeuroRx, Inc.
NeuroRx, Inc.: Form D filings
NeuroRx, Inc., a pharmaceuticals company in Wilmington, DE, filed 2 Form D notices with the SEC in 2016. The latest, on November 23, 2016, reports $2.2 million sold of a $2.2 million offering to 16 investors.
Find out what NeuroRx, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 1201 Orange Street, Suite 600, One Commerce Center, Wilmington, DE, 19801
- Phone
- (212) 643-0417
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2015
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1679768
The full lists. Form D filings in Delaware: 1,342 rows, $67.10, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Nov 23, 2016 | New notice | $2,159,687 | $2,159,687 | $0 | 16 | Nov 10, 2016 | sec.gov |
| Nov 23, 2016 | New notice | $5,541,991 | $4,541,991 | $1,000,000 | 11 | Nov 10, 2016 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Jonathan Javitt | Executive Officer, Director | |
| James Lawrence | Director | |
| Sherry Glied | Director | |
| Chaim Hurvitz | Director | |
| Daniel Javitt | Director |
Every Form D from the week of Nov 21, 2016 · All recent filings in Delaware · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what NeuroRx, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.